Literature DB >> 23287807

Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease.

Pietro Vajro1, Giulia Paolella, Alessio Fasano.   

Abstract

A specific bacterial gut microbiota profile with increased extraction of energy has recently been associated with obesity, which has been shown to be a transmissible phenotype by microbiota transplantation. At the same time, there is now increasing evidence that gut microbiota plays a role in the development of hepatic steatosis and its progression to nonalcoholic steatohepatitis. This review summarizes well known and unexpected interacting factors leading to obesity and its related hepatic diseases, including intestinal mucosal permeability and its regulation, gut microbiota and translocation of its biological products, and gut-associated lymphoid tissue. These intestinal factors dictate also the balance between tolerance and immune response, which are critical for most of the complications in near and far organs or systems. We review novel mechanisms involving the development of gut permeability and adipose tissue plasticity, for example, the cross-talk between the gut microbiota, lipopolysaccharide, high-fat diet, and the endocannabinoid system tone, which have not been fully explored. Interactions between gut microbiota and other factors (eg, inflammasome deficiency) also are reviewed as emerging but far from being completely elucidated mechanisms influencing the onset of obesity and nonalcoholic fatty liver disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23287807      PMCID: PMC3637398          DOI: 10.1097/MPG.0b013e318284abb5

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  50 in total

1.  Gut-liver axis: a new point of attack to treat chronic liver damage?

Authors:  Carmela Loguercio; Teresa De Simone; Alessandro Federico; Fulvia Terracciano; Concetta Tuccillo; Mauro Di Chicco; Maria Cartenì
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

2.  Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial.

Authors:  R Aller; D A De Luis; O Izaola; R Conde; M Gonzalez Sagrado; D Primo; B De La Fuente; J Gonzalez
Journal:  Eur Rev Med Pharmacol Sci       Date:  2011-09       Impact factor: 3.507

Review 3.  Cannabinoid signalling regulates inflammation and energy balance: the importance of the brain-gut axis.

Authors:  Nina L Cluny; Raylene A Reimer; Keith A Sharkey
Journal:  Brain Behav Immun       Date:  2012-01-17       Impact factor: 7.217

4.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.

Authors:  Marc-Emmanuel Dumas; Richard H Barton; Ayo Toye; Olivier Cloarec; Christine Blancher; Alice Rothwell; Jane Fearnside; Roger Tatoud; Véronique Blanc; John C Lindon; Steve C Mitchell; Elaine Holmes; Mark I McCarthy; James Scott; Dominique Gauguier; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

5.  The gut microbiota as an environmental factor that regulates fat storage.

Authors:  Fredrik Bäckhed; Hao Ding; Ting Wang; Lora V Hooper; Gou Young Koh; Andras Nagy; Clay F Semenkovich; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

6.  A moderate weight reduction through dietary intervention decreases hepatic fat content in patients with non-alcoholic fatty liver disease (NAFLD): a pilot study.

Authors:  Valentina Volynets; Jürgen Machann; Markus A Küper; Ina B Maier; Astrid Spruss; Alfred Königsrainer; Stephan C Bischoff; Ina Bergheim
Journal:  Eur J Nutr       Date:  2012-04-28       Impact factor: 5.614

Review 7.  Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer.

Authors:  Alessio Fasano
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

8.  Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study.

Authors:  Irina A Kirpich; Natalia V Solovieva; Svetlana N Leikhter; Natalia A Shidakova; Oxsana V Lebedeva; Pavel I Sidorov; Tatjana A Bazhukova; Andrej G Soloviev; Shirish S Barve; Craig J McClain; Matt Cave
Journal:  Alcohol       Date:  2008-12       Impact factor: 2.405

Review 9.  Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis.

Authors:  F Lirussi; E Mastropasqua; S Orando; R Orlando
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

10.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

View more
  58 in total

Review 1.  The dormant blood microbiome in chronic, inflammatory diseases.

Authors:  Marnie Potgieter; Janette Bester; Douglas B Kell; Etheresia Pretorius
Journal:  FEMS Microbiol Rev       Date:  2015-05-03       Impact factor: 16.408

Review 2.  Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.

Authors:  Giulia Paolella; Claudia Mandato; Luca Pierri; Marco Poeta; Martina Di Stasi; Pietro Vajro
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

3.  Modified apple polysaccharide regulates microbial dysbiosis to suppress high-fat diet-induced obesity in C57BL/6J mice.

Authors:  Yuhua Li; Wenqi Xu; Yang Sun; Yan Wang; Yuan Tang; Yunhua Li; Xiaowei Gao; Can Song; Li Liu; Qibing Mei
Journal:  Eur J Nutr       Date:  2019-07-16       Impact factor: 5.614

4.  Perfluorooctane sulfonate alters gut microbiota-host metabolic homeostasis in mice.

Authors:  Limin Zhang; Bipin Rimal; Robert G Nichols; Yuan Tian; Philip B Smith; Emmanuel Hatzakis; Shu-Ching Chang; John L Butenhoff; Jeffrey M Peters; Andrew D Patterson
Journal:  Toxicology       Date:  2020-01-08       Impact factor: 4.221

5.  Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation.

Authors:  Birju D Bhatt; Thresiamma Lukose; Abby B Siegel; Robert S Brown; Elizabeth C Verna
Journal:  J Gastrointest Oncol       Date:  2015-10

6.  Differences in Metabolic Factors Between Antipsychotic-Induced Weight Gain and Non-pharmacological Obesity in Youths.

Authors:  Simone Pisano; Giangennaro Coppola; Gennaro Catone; Marco Carotenuto; Raffaella Iuliano; Vittoria D'Esposito; Serena Cabaro; Emanuele Miraglia Del Giudice; Carmela Bravaccio; Pietro Formisano
Journal:  Clin Drug Investig       Date:  2018-05       Impact factor: 2.859

Review 7.  Soluble epoxide hydrolase as a therapeutic target for obesity-induced disorders: roles of gut barrier function involved.

Authors:  Jianan Zhang; Maolin Tu; Zhenhua Liu; Guodong Zhang
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2020-09-19       Impact factor: 4.006

8.  Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.

Authors:  Lucia Pacifico; Enea Bonci; Lidia Marandola; Sara Romaggioli; Stefano Bascetta; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Baseline Ultrasound and Clinical Correlates in Children with Cystic Fibrosis.

Authors:  Daniel H Leung; Wen Ye; Jean P Molleston; Alexander Weymann; Simon Ling; Shruti M Paranjape; Rene Romero; Sara Jane Schwarzenberg; Joseph Palermo; Estella M Alonso; Karen F Murray; Bruce C Marshall; Averell H Sherker; Marilyn J Siegel; Rajesh Krishnamurthy; Roger Harned; Boaz Karmazyn; John C Magee; Michael R Narkewicz
Journal:  J Pediatr       Date:  2015-08-05       Impact factor: 4.406

Review 10.  Shared symptoms and putative biological mechanisms in chronic liver disease: implications for biobehavioral research.

Authors:  Victoria Menzies; Nancy Jallo; Patricia Kinser; Jo Lynne W Robins; Kyungeh An; Carolyn Driscoll; Angela Starkweather; Jasmohan S Bajaj; Debra E Lyon
Journal:  Biol Res Nurs       Date:  2014-07-18       Impact factor: 2.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.